Study of Sacituzumab Govitecan Safety and Outcomes in Adults with Metastatic HER2-Negative Breast Cancer

What this Trial Is About

This research aims to evaluate clinical outcomes and safety of Sacituzumab Govitecan in patients with metastatic HER2-negative breast cancer. It focuses on patients who have advanced stage disease and have previously received systemic treatments. The study is observational and sponsored by Fudan University, aiming to gather real-world data on this treatments use in this patient group. Patients included in the study are those with unresectable or metastatic triple-negative breast cancer or HRHER2- breast cancer who have received multiple prior therapies. They receive Sacituzumab Govitecan during the advanced stage of their disease. The study monitors their treatment outcomes and collects data without altering standard care. Participants will be followed regularly according to the study protocol, with assessments including progression-free survival measured six months after the last patient enrollment and overall response rate measured up to 12 weeks. The study also includes safety monitoring and requires adherence to contraceptive measures for those of childbearing potential. The total study duration extends until August 2027.

A Real World Study of Sacituzumab Govitecan